AU2017250010A1 - Composition of proenzymes for cancer treatment - Google Patents

Composition of proenzymes for cancer treatment Download PDF

Info

Publication number
AU2017250010A1
AU2017250010A1 AU2017250010A AU2017250010A AU2017250010A1 AU 2017250010 A1 AU2017250010 A1 AU 2017250010A1 AU 2017250010 A AU2017250010 A AU 2017250010A AU 2017250010 A AU2017250010 A AU 2017250010A AU 2017250010 A1 AU2017250010 A1 AU 2017250010A1
Authority
AU
Australia
Prior art keywords
trypsinogen
chymotrypsinogen
cancer
pct
weight ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017250010A
Other languages
English (en)
Inventor
Ralf Brandt
Julian Kenyon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Propanc Pty Ltd
Original Assignee
Propanc Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propanc Pty Ltd filed Critical Propanc Pty Ltd
Publication of AU2017250010A1 publication Critical patent/AU2017250010A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2017250010A 2016-04-12 2017-04-12 Composition of proenzymes for cancer treatment Abandoned AU2017250010A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662321370P 2016-04-12 2016-04-12
US62/321,370 2016-04-12
PCT/AU2017/050323 WO2017177270A1 (en) 2016-04-12 2017-04-12 Composition of proenzymes for cancer treatment

Publications (1)

Publication Number Publication Date
AU2017250010A1 true AU2017250010A1 (en) 2018-10-11

Family

ID=60041280

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017250010A Abandoned AU2017250010A1 (en) 2016-04-12 2017-04-12 Composition of proenzymes for cancer treatment

Country Status (6)

Country Link
US (1) US20190134166A1 (enExample)
EP (1) EP3442564B1 (enExample)
JP (1) JP7004665B2 (enExample)
CN (1) CN109152823A (enExample)
AU (1) AU2017250010A1 (enExample)
WO (1) WO2017177270A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799208A (zh) * 2017-06-22 2020-02-14 康诺贝林伦瑙有限公司 截短的vwf对fviii免疫原性的调节

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016353539B2 (en) * 2015-11-12 2020-04-23 Propanc Pty Ltd Proenzyme composition
HK1259489A1 (zh) 2015-11-12 2019-11-29 普罗潘克股份有限公司 酶原组合物
IL260814B2 (en) 2016-01-29 2023-04-01 Propanc Pty Ltd Cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514388A (en) * 1983-03-22 1985-04-30 Psaledakis Nicholas G Proteolytic enzymes in the zymogen form to treat sarcoma cells
CZ283972B6 (cs) * 1995-05-17 1998-07-15 František Mudr. Trnka Farmaceutický prostředek s modulačním účinkem na zhoubné nádory a jeho použití
EP2490711A4 (en) * 2009-10-22 2013-04-03 Propanc Pty Ltd PHARMACEUTICAL COMPOSITION FOR CREATING TREATMENT WITH TRYPSINOGENES AND / OR CHYMOTRYPINOGENS AND AN ACTIVE COMPOUNDS SELECTED FROM A SELENIC COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIDE DEDICATOR
CZ307195B6 (cs) * 2013-11-18 2018-03-14 František Trnka Farmaceutická kompozice obsahující směs proenzymů a enzymů
IL260814B2 (en) * 2016-01-29 2023-04-01 Propanc Pty Ltd Cancer treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799208A (zh) * 2017-06-22 2020-02-14 康诺贝林伦瑙有限公司 截短的vwf对fviii免疫原性的调节

Also Published As

Publication number Publication date
EP3442564B1 (en) 2023-12-06
JP7004665B2 (ja) 2022-02-04
CN109152823A (zh) 2019-01-04
JP2019511525A (ja) 2019-04-25
EP3442564A4 (en) 2019-12-04
EP3442564A1 (en) 2019-02-20
WO2017177270A1 (en) 2017-10-19
US20190134166A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
CN102639145B (zh) 包含胰蛋白酶原和/或糜蛋白酶原和选自硒化合物，类香兰素化合物和细胞质糖酵解减少剂的活性剂的用于治疗癌的药物组合物
Brown Matrix metalloproteinase inhibitors: a novel class of anticancer agents
EP3442564B1 (en) Composition of proenzymes for cancer treatment
EP4292606B1 (en) Compositions for treating cancer
CN108430472A (zh) 用于治疗卵巢癌的hdac抑制剂与抗-pd-l1抗体的组合
EP3468559A1 (en) Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
AU2017212151B2 (en) Cancer treatment
AU2016353539B2 (en) Proenzyme composition
US12419938B2 (en) Proenzyme composition
CA3003835C (en) Proenzyme composition
HK40002720A (en) Composition of proenzymes for cancer treatment
CN120712285A (zh) 用以治疗大肠癌的药学试剂盒及其用途
HK1249017B (zh) 包含胰蛋白酶原和糜蛋白酶原的用於治疗癌的药物组合物
HK1228730A (en) Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
HK1228730B (en) Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
HK1228730A1 (en) Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted